桥瑞生物公布口服Infigratinib口服药物在 Achondroplasia 的阶段 3 拟期结果，达到了主要和关键次要指标

summarizeSummary

BridgeBio Pharma announced highly positive Phase 3 topline results for oral infigratinib in children with achondroplasia. The PROPEL 3 study successfully met its primary endpoint of change from baseline in annualized height velocity (AHV) and, notably, achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia for children younger than 8 years old. The drug was well-tolerated with no discontinuations or serious adverse events related to the study drug. These strong results, coupled with the drug's Breakthrough Therapy Designation, pave the way for New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in the second half of 2026. The company also plans to accelerate development for hypochondroplasia, indicating confidence in the drug's mechanism and potential across related conditions. This represents a significant advancement for patients and a major positive catalyst for BridgeBio's pipeline.

check_boxKey Events

• 正面Phase 3初步结果

  口服infigratinib在PROPEL 3研究中成功达到从基线到52周年化身高速度（AHV）的主要终点 (p<.0001) 在 achondroplasia 中。

• First Statistically Significant Improvement in Body Proportionality

  The study achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia, specifically in children younger than 8 years old (p<0.05).

• 良好的耐受性安全性-profile

  口服伊尼格拉替尼耐受良好，没有因研究药物而停止治疗或有严重不良事件，没有与FGFR1或FGFR2抑制相关的不良事件。

• 计划的监管提交

  桥水生物计划在2026年下半年提交新药申请（NDA）和药品批准申请（MAA）用于infigratinib，利用其突破性治疗资格。

auto_awesomeAnalysis

BridgeBio Pharma announced highly positive Phase 3 topline results for oral infigratinib in children with achondroplasia. The PROPEL 3 study successfully met its primary endpoint of change from baseline in annualized height velocity (AHV) and, notably, achieved the first statistically significant improvement in body proportionality against placebo in achondroplasia for children younger than 8 years old. The drug was well-tolerated with no discontinuations or serious adverse events related to the study drug. These strong results, coupled with the drug's Breakthrough Therapy Designation, pave the way for New Drug Application (NDA) and Marketing Authorization Application (MAA) submissions in the second half of 2026. The company also plans to accelerate development for hypochondroplasia, indicating confidence in the drug's mechanism and potential across related conditions. This represents a significant advancement for patients and a major positive catalyst for BridgeBio's pipeline.